Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons and the accumulation of misfolded protein aggregates, including amyloid-beta and alpha-synuclein, in the brain. The search for effective therapeutic strategies to target amyloid aggregation in PD has led to increasing interest in natural compounds, particularly phytochemicals, due to their potential as anti-amyloid agents. This review article provides a comprehensive overview of the current knowledge on phytochemicals as potential therapeutic agents for targeting amyloid aggregation in PD. We summarize the evidence from in vitro and in vivo studies that highlight the anti-amyloid properties of various phytochemicals, including curcumin, resveratrol, epigallocatechin gallate (EGCG), quercetin, and others. We discuss the mechanisms through which these phytochemicals modulate amyloid formation, inhibit aggregation, and promote amyloid clearance. Furthermore, we explore their potential neuroprotective effects, including antioxidant, anti-inflammatory, and anti-apoptotic activities. Additionally, we examine the challenges associated with the development of phytochemical-based therapies, such as bioavailability and pharmacokinetics, and the need for further preclinical and clinical studies. Overall, this review underscores the promising potential of phytochemicals as anti-amyloid agents in PD and highlights the need for continued research to fully understand their mechanisms of action, optimize their therapeutic properties, and facilitate their translation into clinical practice for the benefit of PD patients.